Fort Worth · Seed–Growth · 16 people tracked
Also known as BIOS CAPITAL MANAGEMENT, LP · STEELHEAD CAPITAL MANAGEMENT, LLC
Investment thesis
Bios Partners argues that scientific talent is distributed evenly across the country while venture capital concentrates on the coasts, particularly Silicon Valley and the Northeastern US. The firm seeks to disrupt this 'geographic favoritism' by investing in scientifically compelling opportunities in the Central US that are typically overlooked and undervalued. Its approach centers on company cultivation and is driven by science, drawing on a team with combined experience across hedge funds, private equity, clinical drug development, and public pharma/biotech analysis.
Source: firm website, verified Aug 25, 2026.
Team · 16 people
from the firm's website & curated & public directories
What they invest in
from 10 of 10 portfolio companiesBiotech ×8Healthtech ×6Medical Devices ×4AI & Machine Learning ×2Cloud Computing ×1Cybersecurity ×1Deep Tech ×1Hardware ×1
HQs:United States×9
Investments · 10 tracked
founders shown can be your intro pathBy year:2025 · 12023 · 12022 · 22021 · 22020 · 12018 · 12015 · 19 dated
Clinical-stage therapeutics company focusing on high-impact cancers and inflammatory diseases.
BiotechFort Worth, US
Daniel Schmitt(Executive Officer, Director)Paul Lytle(Executive Officer)Andrew Mazar(Executive Officer)
BoardTodd Thomson(Director)inRoger Sawhney(Director)Jason Keyes(Director)
Board seatAaron G.L. FletcherLeslie W. Kreis, Jr.· per SEC Form D
Co-investorsIllinois VenturesKairos Venture Investments, LlcBios
Azitra is a clinical-stage biopharmaceutical company developing genetically engineered bacteria and proteins for treating skin diseases through precision dermatology.
AI & Machine LearningBiotechHealthtechFarmington, US
Azim Munivar(Executive Officer, Director, Promoter)
Board seatStella RobertsonTravis Whitfill· per SEC Form D · $4.5M raise · filed Oct 2022
Co-investorsKdT Ventures
Cue Biopharma is a precision immunotherapy company developing engineered therapies targeting allergic and autoimmune diseases.
BiotechHealthtechMedical DevicesBoston, US
Daniel Baker(Executive Officer)Colin Sandercock(Executive Officer)Dominic Borie(Chief Medical Officer and Head of Research and Development)Sumita Ray(Executive Officer)Michael Meluzio(Executive Officer)Rodolfo Chaparro(Vice President, Head of Immunology)
Board seatAaron G.L. Fletcher· per SEC Form D · $30M raise · filed Nov 2022
Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases.
BiotechHealthtechMedical DevicesSan Diego, US
David Eveleth(Executive Officer, Director)Schalon Newton(Executive Officer)
BoardChristy Shaffer(Director)inRalph Bradshaw(Director)
Board seatStella Robertson· per SEC Form D
Co-investorsExSight VenturesSolasta VenturesAccess BiotechnologyCorrelation VenturesFemHealth VenturesHatteras Venture Partners+2 more
ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.
BiotechHealthtechMedical DevicesAnn Arbor, US
David Zacks(Co-Founder & Chief Scientific Officer)David N Zacks(Executive Officer, Director)David Esposito(Executive Officer, Director)Constance Chang(Executive Officer)John K Freshley(Executive Officer, Director)Jeffrey A Jamison(Executive Officer)
Co-investorsExSight VenturesInvest MichiganNovartis Venture FundVisionary VenturesInFocus Capital Partners, LLCJohnson & Johnson Innovation – JJDC+3 more
410 Medical makes LifeFlow, a hand-operated rapid infuser that lets clinicians quickly deliver blood or fluids to critically ill patients needing volume resuscitation.
HardwareHealthtechMedical DevicesDurham, US
Mark Donald Piehl(Executive Officer, Director)KYLE CHENET(Executive Officer, Director)
BoardJEFF TERRELL(Director)inSTANLEY D. LYNALL(Director)FRED GOLDWATER(Director)inMAYANK TANEJA(Director)in
Board seatTravis Whitfill· per SEC Form D · $4M raise · filed Aug 2018
Co-investorsBallad VenturesCU Healthcare Innovation FundDuke Capital PartnersOSF VenturesWolfpack Investor NetworkHatteras Venture Partners
BiotechHummelstown, US
Stephen C. Rocamboli(Executive Officer, Director)Rifat Pamukcu(Director)Robert Towarnicki(Executive Officer, Director)Roger Sawhney(Director)
BoardJohn Fucci(Director)in
Board seatTim Van Treuren· per SEC Form D · $42.1M raise · filed Jan 2024
Co-investorsBioAdvanceLife Sciences Greenhouse Investments
BiotechAustin, US
James Brian Windsor(President and CEO)Steven Idell(Director)
BoardAaron Fletcher(Director)inJoseph Woelkers(Director)Robert Mills(Director)
Board seatAaron G.L. Fletcher· per SEC Form D · $15M raise · filed Apr 2022
Co-investorsUT Horizon Fund
Actuate provides AI video analytics that integrate with existing camera systems and video monitoring software to detect threats such as guns, intruders, crowds, unauthorized access, and fire while reducing false alarms.
AI & Machine LearningCloud ComputingCybersecurity
Sonny Tai(Founder)
Co-investorsBling CapitalDorm RoomGray Line PartnersMetaPropMetaProp VenturesScribble Ventures+3 more
Stream Biomedical is a clinical-stage biotechnology company developing LG3, a biologic derived from a natural repair protein intended to protect and restore the brain by activating its repair systems.
BiotechDeep TechHealthtechHouston, US
H. Davis Adkisson(Chief Scientific Officer)Chris Garabedian(Director)William Schwieterman(Board of Directors)Fred Callori(Director)
BoardAmanda De La Garza(Director)in
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 3
IPOs and acquisitions across the tracked portfolioActuate TherapeuticsNASDAQ: ACTUAzitraNYSE: AZTRCue BiopharmaNASDAQ: CUE
Portfolio news
latest coverage across their companies
Actuate Therapeutics · stocktitan.net · Aug 14, 2026
Actuate · stocktitan.net · Aug 14, 2026
Cue Biopharma · manilatimes.net · Aug 14, 2026
Trefoil Therapeutics · hatterasvp.com · Jan 9, 2026
BobcatBio · tinytechfund.com · Mar 13, 2025
Frequently asked questions
- What stage does Bios Partners invest at?
- Bios Partners invests at the Seed, Series A, Series B, Series C, Growth stages.
- What sectors does Bios Partners focus on?
- Bios Partners focuses on Biotech, Healthtech, Medical Devices.
- Where is Bios Partners located?
- Bios Partners is headquartered in Fort Worth, US.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.